Philippe Menu Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $7.52, for a total value of $37,600.00. Following the sale, the insider directly owned 218,387 shares of the company’s stock, valued at $1,642,270.24. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Price Performance

Shares of SOPH opened at $7.50 on Friday. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $7.88. The stock’s 50 day moving average is $5.89 and its two-hundred day moving average is $5.23. The firm has a market capitalization of $629.17 million, a PE ratio of -6.52 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the subject of a number of recent analyst reports. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, HC Wainwright upped their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Trading of SOPHiA GENETICS

Several hedge funds and other institutional investors have recently bought and sold shares of SOPH. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.